open access

Vol 6, No 3 (2010)
Review paper
Published online: 2010-08-27
Get Citation

The modern diagnosis and intrathecal therapy of the neoplastic meningitis in adults solid neoplasms

Piotr Plecka
Onkol. Prak. Klin 2010;6(3):97-103.

open access

Vol 6, No 3 (2010)
REVIEW ARTICLES
Published online: 2010-08-27

Abstract

Nowadays there are more recognized rare oncologic cases because of introducing sophisticated diagnostic methods to everyday clinical practice. The example of this is the neoplastic meningitis. This in turn augments the development of better therapeutic procedures. In the diagnostic sector, to well-known tools such as myelo-KT, nuclear magnetic resonance (NMR), lumbar puncture with cytologic and biochemical examination of the fluid or flow scintigraphy of the cerebrospinal fluid, came to existence new devices like positron emission tomography (PET) and specific chemical substances tests in the fluid, connected with the presence of the exact oncologic entity (Ca 15.3, LDH, angiogenesis markers, interleukins).
The new therapeutic options are directly connected with improved diagnostic methods of the central nervous system. The liposomal formulations of the previously used cytotoxic drugs for intrathecal therapy emerged (methotrexat, cytarabine), which have improved central nervous system penetration ability and their longer life half-time prolongs the time to the next lumbar puncture. There are introduced completely new substances so called immunomodulators (trastuzumab, rituximab, interferons), which aim selectively for neoplastic cells.
Those aforementioned improvements prolonged the life time of the neoplastic meningitis patients and increased its quality. But there is a constant demand for improving current methods and exploring new approaches.
Onkol. Prak. Klin. 2010; 6, 3: 97–103

Abstract

Nowadays there are more recognized rare oncologic cases because of introducing sophisticated diagnostic methods to everyday clinical practice. The example of this is the neoplastic meningitis. This in turn augments the development of better therapeutic procedures. In the diagnostic sector, to well-known tools such as myelo-KT, nuclear magnetic resonance (NMR), lumbar puncture with cytologic and biochemical examination of the fluid or flow scintigraphy of the cerebrospinal fluid, came to existence new devices like positron emission tomography (PET) and specific chemical substances tests in the fluid, connected with the presence of the exact oncologic entity (Ca 15.3, LDH, angiogenesis markers, interleukins).
The new therapeutic options are directly connected with improved diagnostic methods of the central nervous system. The liposomal formulations of the previously used cytotoxic drugs for intrathecal therapy emerged (methotrexat, cytarabine), which have improved central nervous system penetration ability and their longer life half-time prolongs the time to the next lumbar puncture. There are introduced completely new substances so called immunomodulators (trastuzumab, rituximab, interferons), which aim selectively for neoplastic cells.
Those aforementioned improvements prolonged the life time of the neoplastic meningitis patients and increased its quality. But there is a constant demand for improving current methods and exploring new approaches.
Onkol. Prak. Klin. 2010; 6, 3: 97–103
Get Citation

Keywords

intrathecal therapy; neoplastic meningitis; PET

About this article
Title

The modern diagnosis and intrathecal therapy of the neoplastic meningitis in adults solid neoplasms

Journal

Oncology in Clinical Practice

Issue

Vol 6, No 3 (2010)

Article type

Review paper

Pages

97-103

Published online

2010-08-27

Bibliographic record

Onkol. Prak. Klin 2010;6(3):97-103.

Keywords

intrathecal therapy
neoplastic meningitis
PET

Authors

Piotr Plecka

References (44)
  1. Boogerd W, Hart A, Sande Jv, et al. Meningeal carcinomatosis in breast cancer. Prognostic factors and influence of treatment. Cancer. 1991; 67(6): 1685–1695, doi: 10.1002/1097-0142(19910315)67:6<1685::aid-cncr2820670635>3.0.co;2-m.
  2. Chamberlain MC. Neoplastic meningitis. Semin Neurol. 2004; 24(4): 363–374.
  3. Giglio P, Weinberg JS, Forman AD, et al. Neoplastic meningitis in patients with adenocarcinoma of the gastrointestinal tract. Cancer. 2005; 103(11): 2355–2362.
  4. Hitchins RN, Bell DR, Woods RL, et al. A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis. J Clin Oncol. 1987; 5(10): 1655–1662.
  5. Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer. J Clin Oncol. 2004; 22(17): 3608–3617.
  6. Jayson GC, Howell A, Harris M, et al. Carcinomatous meningitis in patients with breast cancer. An aggressive disease variant. Cancer. 1994; 74(12): 3135–3141.
  7. Wong ET, Joseph JT. Meningeal carcinomatosis in lung cancer. Case 1. Carcinomatous leptomeningeal metastases. J Clin Oncol. 2000; 18(15): 2926–2927.
  8. Jänne PA, Janicek MJ, Brown F. Meningeal carcinomatosis in lung cancer. Case 2. Carcinomatous meningitis. J Clin Oncol. 2000; 18(15): 2927–2929.
  9. Drappatz J, Batchelor TT. Leptomeningeal metastasis. Proc Am Soc Clin Oncol. 2009: 100–105.
  10. Rudnicka H, Niwińska A, Murawska M. Breast cancer leptomeningeal metastasis--the role of multimodality treatment. J Neurooncol. 2007; 84(1): 57–62.
  11. Balm M, Hammack J. Leptomeningeal carcinomatosis. Presenting features and prognostic factors. Arch Neurol. 1996; 53(7): 626–632.
  12. Wasserstrom WR, Glass JP, Posner JB. Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer. 1982; 49(4): 759–772.
  13. Olson ME, Chernik NL, Posner JB. Infiltration of the leptomeninges by systemic cancer. A clinical and pathologic study. Arch Neurol. 1974; 30(2): 122–137.
  14. Grisold W, Drlicek M, Setinek ULC. clinical syndrome in different primaries. J Neurooncol. 1998; 30: 103–110.
  15. Fizazi K, Asselain B, Vincent-Salomon A, et al. Meningeal carcinomatosis in patients with breast carcinoma: Clinical features, prognostic factors, and results of a high-dose intrathecal methotrexate regimen. Cancer. 1996; 77(7): 1315–1323, doi: 10.1002/(sici)1097-0142(19960401)77:7<1315::aid-cncr14>3.0.co;2-4.
  16. Altundag K, Bondy ML, Mirza NQ, et al. Clinicopathologic characteristics and prognostic factors in 420 metastatic breast cancer patients with central nervous system metastasis. Cancer. 2007; 110(12): 2640–2647.
  17. Schumacher M, Orszagh M. Imaging techniques in neoplastic meningiosis. J Neurooncol. 1998; 38(2-3): 111–120.
  18. Freilich RJ, Krol G, DeAngelis LM. Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis. Ann Neurol. 1995; 38(1): 51–57.
  19. Chamberlain MC, Sandy AD, Press GA. Leptomeningeal metastasis: a comparison of gadolinium-enhanced MR and contrast-enhanced CT of the brain. Neurology. 1990; 40(3 Pt 1): 435–438.
  20. Gleissner B, Chamberlain MC. Neoplastic meningitis. Lancet Neurol. 2006; 5(5): 443–452.
  21. Gomori JM, Heching N, Siegal T. Leptomeningeal metastases: evaluation by gadolinium enhanced spinal magnetic resonance imaging. J Neurooncol. 1998; 36(1): 55–60.
  22. Sculier JP. Prognostic factors and implications of positron emission tomography. Proc Am Soc Clin Oncol. 2009: 469–472.
  23. Chawla M, Reddy R, Kumar R, et al. PET-CT in detection of meningeal metastasis in neuroblastoma. Pediatr Surg Int. 2009; 25(2): 211–215.
  24. KOMORI T, DELBEKE D. Leptomeningeal Carcinomatosis and Intramedullary Spinal Cord Metastases from Lung Cancer. Clinical Nuclear Medicine. 2001; 26(11): 905–907.
  25. Rangarajan V, Purandare N, Luthra K, et al. 18F-FDG uptakes in leptomeningeal metastases from carcinoma of the breast on a positron emission tomography/computerized tomography study. Indian Journal of Cancer. 2007; 44(3): 115–118.
  26. DeAngelis LM. Current diagnosis and treatment of leptomeningeal metastasis. J Neurooncol. 1998; 38(2-3): 245–252.
  27. Twijnstra A, Ongerboer de Visser BW, van Zanten AP, et al. Serial lumbar and ventricular cerebrospinal fluid biochemical marker measurements in patients with leptomeningeal metastases from solid and hematological tumors. J Neurooncol. 1989; 7(1): 57–63.
  28. Lossos IS, Breuer R, Intrator O, et al. Cerebrospinal fluid lactate dehydrogenase isoenzyme analysis for the diagnosis of central nervous system involvement in hematooncologic patients. Cancer. 2000; 88(7): 1599–1604.
  29. MacKenzie JM. Malignant meningitis: a rational approach to cerebrospinal fluid cytology. J Clin Pathol. 1996; 49(6): 497–499.
  30. Müller HL, Oh Y, Gargosky SE, et al. Concentrations of insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3), IGF, and IGFBP-3 protease activity in cerebrospinal fluid of children with leukemia, central nervous system tumor, or meningitis. J Clin Endocrinol Metab. 1993; 77(5): 1113–1119.
  31. Stockhammer G, Poewe W, Burgstaller S, et al. Vascular endothelial growth factor in CSF: a biological marker for carcinomatous meningitis. Neurology. 2000; 54(8): 1670–1676.
  32. Reijneveld JC, Brandsma D, Boogerd W, et al. CSF levels of angiogenesis-related proteins in patients with leptomeningeal metastases. Neurology. 2005; 65(7): 1120–1122.
  33. Brandsma D, Taphoorn MJB, de Jager W, et al. Interleukin-8 CSF levels predict survival in patients with leptomeningeal metastases. Neurology. 2006; 66(2): 243–246.
  34. Friedberg M, Glantz M, Klempner M, et al. Specific matrix metalloproteinase profiles in the cerebrospinal fluid correlated with the presence of malignant astrocytomas, brain metastases, and carcinomatous meningitis. Cancer. 1998; 82(5): 923–930, doi: 10.1002/(sici)1097-0142(19980301)82:5<923::aid-cncr18>3.0.co;2-2.
  35. Jolivet J, Cowan KH, Curt GA, et al. The pharmacology and clinical use of methotrexate. N Engl J Med. 1983; 309(18): 1094–1104.
  36. Ackland SP, Schilsky RL. High-dose methotrexate: a critical reappraisal. J Clin Oncol. 1987; 5(12): 2017–2031.
  37. Grossman SA, Finkelstein DM, Ruckdeschel JC, et al. Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group. J Clin Oncol. 1993; 11(3): 561–569.
  38. Fulton DS, Levin VA, Gutin PH, et al. Intrathecal cytosine arabinoside for the treatment of meningeal metastases from malignant brain tumors and systemic tumors. Cancer Chemother Pharmacol. 1982; 8(3): 285–291.
  39. Stemmler HJ, Schmitt M, Harbeck N, et al. Application of intrathecal trastuzumab (Herceptintrade mark) for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer. Oncol Rep. 2006; 15(5): 1373–1377.
  40. Laufman LR, Forsthoefel KF. Use of intrathecal trastuzumab in a patient with carcinomatous meningitis. Clin Breast Cancer. 2001; 2(3): 235.
  41. Chamberlain MC. A phase II trial of intra-cerebrospinal fluid alpha interferon in the treatment of neoplastic meningitis. Cancer. 2002; 94(10): 2675–2680.
  42. Glantz MJ, Jaeckle KA, Chamberlain MC, et al. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res. 1999; 5(11): 3394–3402.
  43. Jaeckle KA, Batchelor T, O'Day SJ, et al. An open label trial of sustained-release cytarabine (DepoCyt) for the intrathecal treatment of solid tumor neoplastic meningitis. J Neurooncol. 2002; 57(3): 231–239.
  44. Cheng TM, O'Neill BP, Scheithauer BW, et al. Chronic meningitis: the role of meningeal or cortical biopsy. Neurosurgery. 1994; 34(4): 590–5; discussion 596.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl